Lead sponsor
AstraZeneca
136 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
136
Trials led
11
Ongoing
729,042
Total enrollment
2,469
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
32
Phase 1/2
2
Phase 2
33
Phase 3
47
Phase 4
7
Not applicable
15
Trials by status
Not yet recruiting
1
Recruiting
6
Active, not recruiting
4
Completed
119
Terminated
5
Withdrawn
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents-not applicableCompleted363,766
Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy-not applicableCompleted15,498
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes MellitusHbA1c 6.5-10%Ph 3Completed14,752
Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins-not applicableCompleted7,000
Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment-not applicableCompleted6,024
Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)-not applicableCompleted2,948
CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy-not applicableCompleted2,515
Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea-not applicableCompleted1,711
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 DiabetesHbA1c ≤9%not applicableCompleted1,297
Specific Clinical Experience Investigation for Long-term Use of Bydureon.-not applicableCompleted1,137
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 DiabetesBMI 25-45Ph 3Completed1,036
Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 DiabetesBMI ≤45Ph 3Completed912
Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 DiabetesHbA1c ≥7%not applicableCompleted888
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 DiabetesBMI ≥25Ph 2Completed834
Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)BMI 23-45Ph 3Completed820
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes MellitusBMI 27-45Ph 3Completed734
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching PlaceboHbA1c 8-12%Ph 3Completed695
A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian SubjectsBMI 21-35Ph 3Completed691
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsBMI 30-35Ph 2Completed636
Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and MetforminHbA1c 7-10%Ph 3Completed551
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)BMI 25-45Ph 3Completed514
Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and MetforminBMI 25-40Ph 3Completed505
Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 DiabetesBMI 25-40Ph 3Completed494
Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)BMI 25-45Ph 3Completed467
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and MetforminBMI 21-35Ph 3Completed466
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes MellitusHbA1c 7.5-12%Ph 3Completed464
Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 DiabetesBMI 25-45Ph 3Completed456
Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes MellitusBMI 18-35Ph 3Completed427
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes MellitusHbA1c 7-11%Ph 3Completed400
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese SubjectsBMI 30-50Ph 2Completed400
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a SulfonylureaBMI 27-45Ph 3Completed377
Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 DiabetesBMI 25-45Ph 3Completed377
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With MetforminBMI 27-45Ph 3Completed336
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)BMI 25-45Ph 3Completed303
Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose ControlHbA1c 7.5-9%Ph 3Completed296
An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus-Ph 3Completed275
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese SubjectsBMI 30-50Ph 2Completed258
A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus MetforminBMI 20-45Ph 4Completed255
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)BMI 25-45Ph 3Completed254
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes MellitusBMI ≥25Ph 2Completed248
Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.HbA1c 7-10%Ph 4Completed239
A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes PatientsBMI ≥27Ph 3Completed235
Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 DiabetesBMI 25-45Ph 3Completed222
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese SubjectsBMI 35-45Ph 2Terminated213
A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects-Ph 2Completed210
A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 DiabetesBMI 25-45Ph 4Completed200
Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus-Ph 3Completed190
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese SubjectsBMI 30-45Ph 2Completed184
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and MetforminBMI 25-45Ph 3Completed182
Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)HbA1c 7-10%Ph 3Completed181
A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese SubjectsBMI 30-35Ph 2Completed177
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and MetforminBMI ≤45Ph 3Completed165
A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese PatientsBMI ≥30Ph 2Completed163
Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes MellitusBMI 27-45Ph 2Completed156
Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea CombinationBMI 25-45Ph 3Completed155
A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes-Ph 2Completed153
Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate TherapyBMI 25-40Ph 3Completed138
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes MellitusBMI 25-40Ph 3Completed137
Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With MetforminBMI 25-45Ph 3Completed134
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 DiabetesHbA1c 6.5-10.5%Ph 3Completed122
A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly SuspensionHbA1c 7.1-11%Ph 2Completed121
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 DiabetesBMI 25-50Ph 4Completed112
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or ObeseBMI 25-40Ph 1Completed104
A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes MellitusBMI 25-45Ph 4Completed102
Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus-Ph 2Completed99
A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy SubjectsBMI 25-35Ph 1Completed94
Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 DiabetesHbA1c 6.5-11%Ph 3Completed84
Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a ThiazolidinedioneBMI 25-45Ph 4Completed83
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With MetforminBMI 27-40Ph 2Terminated80
Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy SubjectsBMI 19-35Ph 1Completed70
A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly SuspensionBMI 23-35Ph 1/2Completed65
A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 YearsBMI ≥23Ph 1Active, not recruiting65
Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 DiabetesBMI 24-40Ph 2Completed61
An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 DiabetesHbA1c ≤10.5%Ph 3Completed58
A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 DiabetesBMI 25-40Ph 3Completed54
Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or ObeseBMI 25-35Ph 1Completed54
A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female ParticipantsBMI 18.5-35Ph 1Completed51
Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic AgentsBMI 27-40Ph 2Completed49
A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy ParticipantsBMI 20-35Ph 1Completed49
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy ParticipantsBMI 18-30Ph 1Completed48
Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I DiabetesBMI ≥20Ph 2Completed47
Study Examining Exenatide Long-Acting Release in Subjects With Type 2 DiabetesBMI 25-45Ph 2Completed45
Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients-not applicableCompleted41
The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy FemalesBMI 19-35Ph 1Completed38
A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes MellitusBMI 18-32Ph 1Completed35
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes MellitusBMI ≤30Ph 1Completed34
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004BMI 18-40Ph 1Completed33
A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy ParticipantsBMI 18-35Ph 1Active, not recruiting32
Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DMBMI ≤30Ph 1Completed32
A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy ParticipantsBMI 18-29.9Ph 1Terminated31
A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy ParticipantsBMI ≥23Ph 1Completed31
A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 DiabetesHbA1c 6.5-10%Ph 1Completed30
Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 DiabetesBMI 25-50Ph 2Completed30
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234BMI 18-42Ph 1Recruiting28
Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234BMI 18-40Ph 1Completed24
Evaluation of an Orally Administered Medication When Taken in Conjunction With PramlintideHbA1c 6.5-11%Ph 2Completed24
A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234BMI 25-35Ph 1Recruiting21
A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 DiabetesBMI 19-40Ph 1Completed17
Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes MelitusBMI 25-35Ph 1Completed16
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004BMI 18-40Ph 1Completed16
A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral FormulationsBMI ≥23Ph 1Completed16
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightBMI ≥27Ph 2Recruiting14
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes MellitusHbA1c 6-11%Ph 2Completed13
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes MellitusHbA1c 6-10%Ph 2Completed12
A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy SubjectsBMI 18-30Ph 1Completed10
A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004BMI 18-35Ph 1Completed8
Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes MellitusBMI 18.5-35Ph 1Withdrawnnot disclosed